Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

US11274316B2 · kind B2 · utility

Assignee

• CELLECTIS · FR

Inventors

• Roman Galetto · Paris, FR
• Agnes Gouble · Paris, FR
• Stephanie GROSSE · Coulommiers, FR
• Cecile Mannioui · Villiers sur Marne, FR
• Laurent POIROT · Paris, FR
• Andrew M. Scharenberg · Seattle, US
• Julianne Smith · New York, US

Key dates

• Filing date: Mar 11, 2021
• Grant date: Mar 15, 2022
• Expiry date: Mar 11, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.